1. Home
  2. KOP vs BCYC Comparison

KOP vs BCYC Comparison

Compare KOP & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KOP
  • BCYC
  • Stock Information
  • Founded
  • KOP 1988
  • BCYC 2009
  • Country
  • KOP United States
  • BCYC United Kingdom
  • Employees
  • KOP N/A
  • BCYC N/A
  • Industry
  • KOP Forest Products
  • BCYC Biotechnology: Pharmaceutical Preparations
  • Sector
  • KOP Basic Materials
  • BCYC Health Care
  • Exchange
  • KOP Nasdaq
  • BCYC Nasdaq
  • Market Cap
  • KOP 631.3M
  • BCYC 566.5M
  • IPO Year
  • KOP 2006
  • BCYC 2019
  • Fundamental
  • Price
  • KOP $32.15
  • BCYC $8.55
  • Analyst Decision
  • KOP Buy
  • BCYC Buy
  • Analyst Count
  • KOP 1
  • BCYC 10
  • Target Price
  • KOP $64.00
  • BCYC $25.00
  • AVG Volume (30 Days)
  • KOP 163.2K
  • BCYC 280.5K
  • Earning Date
  • KOP 05-09-2025
  • BCYC 08-05-2025
  • Dividend Yield
  • KOP 0.99%
  • BCYC N/A
  • EPS Growth
  • KOP N/A
  • BCYC N/A
  • EPS
  • KOP 1.22
  • BCYC N/A
  • Revenue
  • KOP $2,051,000,000.00
  • BCYC $25,722,000.00
  • Revenue This Year
  • KOP N/A
  • BCYC $7.83
  • Revenue Next Year
  • KOP N/A
  • BCYC N/A
  • P/E Ratio
  • KOP $25.79
  • BCYC N/A
  • Revenue Growth
  • KOP N/A
  • BCYC N/A
  • 52 Week Low
  • KOP $22.99
  • BCYC $6.10
  • 52 Week High
  • KOP $44.19
  • BCYC $28.67
  • Technical
  • Relative Strength Index (RSI)
  • KOP 67.50
  • BCYC 53.13
  • Support Level
  • KOP $31.14
  • BCYC $8.19
  • Resistance Level
  • KOP $31.99
  • BCYC $8.75
  • Average True Range (ATR)
  • KOP 0.74
  • BCYC 0.45
  • MACD
  • KOP -0.03
  • BCYC 0.04
  • Stochastic Oscillator
  • KOP 93.23
  • BCYC 60.55

About KOP Koppers Holdings Inc.

Koppers Holdings Inc through its subsidiaries, manufactures and sells wood products, wood treatment chemicals, and carbon compounds used in markets such as railroad, aluminum and steel, agriculture, utilities, and residential lumber. The company is organized into three business segments: railroad and utility products and services, performance chemicals, and carbon materials and chemicals. Its product portfolio includes treated and untreated wood products like crossties used in railroads, wood preservation chemicals, and carbon compounds such as creosote used in the treatment of wood crossties, among others. The majority of its revenue comes from the company's railroad and utility products and services segment, and more than half of the company's revenue is earned in the United States.

About BCYC Bicycle Therapeutics plc

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.

Share on Social Networks: